Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 10/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096058 | 0.88 | LMNA (0.61) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL5204724 | 0.82 | THRA (0.44) | MAOAGAARAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL6629023 | 0.82 | BCHE (0.51) | BCHEMAOBALOX5EGFRERBB2 | |
| SCHEMBL7290118 | 0.81 | BCHE (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL20803040 | 0.81 | GAA (0.59) | CYP1A2BCHEMAOBMCL1GAA | |
| SCHEMBL1550410 | 0.80 | MAOB (0.58) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL5111326 | 0.80 | BCHE (0.49) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL3919862 | 0.79 | LMNA (0.51) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL7163366 | 0.79 | BCHE (0.48) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8599201 | 0.79 | LMNA (0.68) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381613-B1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF OXAHETEROCYCLE-FUSED-(1,4)-BENZODIOXANS | WYETH CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| CN-1503798-A | Antidepressant azaheterocyclylmethyl derivatives of oxacyclo-fused- [1,4] benzodioxans | — | 2004-06-09 | — | — | CN | disclosed |
| US-6706736-B2 | AMINES SUCH AS 3-(1-((8-METHYL-2,3-DIHYDROFURO(2,3-F)(1,4) BENZODIOXIN-2-YL)METHYL)-1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE, ADMINISTERED AS SEROTONIN REUPTAKE INHIBITORS OR ANXIOLYTIC AGENTS | WYETH | 2004-03-16 | — | — | US | disclosed |
| EP-1381613-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF OXAHETEROCYCLE-FUSED- 1,4]-BENZODIOXANS | Wyeth (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030162805-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | WYETH (US) | 2003-08-28 | — | — | US | disclosed |
| US-6552049-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-04-22 | — | — | US | disclosed |
| US-20020183353-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | WYETH (US) | 2002-12-05 | — | — | US | disclosed |
| WO-2002088135-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF OXAHETEROCYCLE-FUSED-[1,4]-BENZODIOXANS | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162805-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | OPRD1, OPRM1, OPRK1 | LMNA 4362/4885CYP1A2 195/4885PTGS1 1600/4885 |
| US-20020183353-A1 | Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans | OPRD1, OPRM1, OPRK1 | LMNA 4325/4885CYP1A2 249/4885PTGS1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.